TORONTO, April 27 /CNW/ - Transition Therapeutics Inc. (“Transition”) (TSX: TTH), announced today that they have received clearance from the Therapeutic Products Directorate of Health Canada to initiate a Phase I clinical trial for lead Alzheimer’s product, AZD-103. The AZD-103 compound is a promising disease-modifying therapeutic candidate for the treatment of Alzheimer’s disease. This unique class of therapeutics provides significant advantages over the current products on the market which only treat disease symptoms.
